Logo image of BLRX

BIOLINERX LTD-SPONS ADR (BLRX) Stock Fundamental Analysis

NASDAQ:BLRX - Nasdaq - US09071M2052 - ADR - Currency: USD

5.44  -0.38 (-6.53%)

After market: 5.29 -0.15 (-2.76%)

Fundamental Rating

1

Taking everything into account, BLRX scores 1 out of 10 in our fundamental rating. BLRX was compared to 559 industry peers in the Biotechnology industry. Both the profitability and financial health of BLRX have multiple concerns. BLRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BLRX has reported negative net income.
BLRX had a negative operating cash flow in the past year.
In the past 5 years BLRX always reported negative net income.
BLRX had a negative operating cash flow in each of the past 5 years.
BLRX Yearly Net Income VS EBIT VS OCF VS FCFBLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of BLRX (-23.70%) is better than 75.49% of its industry peers.
The Return On Equity of BLRX (-68.50%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -23.7%
ROE -68.5%
ROIC N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
BLRX Yearly ROA, ROE, ROICBLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

BLRX's Gross Margin of 67.99% is amongst the best of the industry. BLRX outperforms 81.40% of its industry peers.
BLRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLRX Yearly Profit, Operating, Gross MarginsBLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

BLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLRX has more shares outstanding
BLRX has a worse debt/assets ratio than last year.
BLRX Yearly Shares OutstandingBLRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BLRX Yearly Total Debt VS Total AssetsBLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.59, we must say that BLRX is in the distress zone and has some risk of bankruptcy.
BLRX has a worse Altman-Z score (-13.59) than 78.89% of its industry peers.
BLRX has a Debt/Equity ratio of 0.75. This is a neutral value indicating BLRX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.75, BLRX is doing worse than 75.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Altman-Z -13.59
ROIC/WACCN/A
WACC31.01%
BLRX Yearly LT Debt VS Equity VS FCFBLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 1.76 indicates that BLRX should not have too much problems paying its short term obligations.
The Current ratio of BLRX (1.76) is worse than 78.71% of its industry peers.
BLRX has a Quick Ratio of 1.56. This is a normal value and indicates that BLRX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BLRX (1.56) is worse than 79.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.56
BLRX Yearly Current Assets VS Current LiabilitesBLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.19% over the past year.
Looking at the last year, BLRX shows a very strong growth in Revenue. The Revenue has grown by 502.92%.
EPS 1Y (TTM)88.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.4%
Revenue 1Y (TTM)502.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.77%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLRX Yearly Revenue VS EstimatesBLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 5M 10M 15M 20M 25M
BLRX Yearly EPS VS EstimatesBLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLRX Price Earnings VS Forward Price EarningsBLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLRX Per share dataBLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOLINERX LTD-SPONS ADR

NASDAQ:BLRX (6/11/2025, 5:38:09 PM)

After market: 5.29 -0.15 (-2.76%)

5.44

-0.38 (-6.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17 2025-02-17
Earnings (Next)N/A N/A
Inst Owners0.04%
Inst Owner Change-71.45%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap20.24M
Analysts100
Price TargetN/A
Short Float %5.06%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 1.5
P/tB 6.72
EV/EBITDA N/A
EPS(TTM)-2.64
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-11.81
FCFYN/A
OCF(TTM)-11.79
OCFYN/A
SpS7.78
BVpS3.62
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.7%
ROE -68.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.99%
FCFM N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.33%
Cap/Sales 0.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.76
Quick Ratio 1.56
Altman-Z -13.59
F-Score4
WACC31.01%
ROIC/WACCN/A
Cap/Depr(3y)23.7%
Cap/Depr(5y)16.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.4%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)502.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-91.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.06%
OCF growth 3YN/A
OCF growth 5YN/A